Efficacy of SGLT2 inhibitors in heart failure patients with preserved left ventricular function

Efficacy of SGLT2 inhibitors in heart failure patients with preserved left ventricular function - Efficacy of SGLT2 inhibitors in heart failure patients with preserved left ventricular function

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053988

Enrollment

Registered

2024-03-27

Start date

2021-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Heart failure patients with preserved left ventricular function in whom SGLT2 inhibitors were initiated in chronic heart failure, chronic kidney disease or diabetes mellitus

Exclusion criteria

Exclusion criteria: Persons who have difficulty in obtaining consent in person Persons who have refused to participate in the study. Other persons deemed unsuitable as research subjects by the principal investigator.

Design outcomes

Primary

Measure	Time frame
Change in hepcidin and exercise tolerance measured six months after induction of SGLT2 inhibitors	—

Secondary

Measure	Time frame
NT-proBNP, cardiac MRI (fibrosis, atrial and ventricular capacitance, and functional parameters) Changes in hematopoietic, renal, and skeletal muscle parameters	—

Countries

Japan

Contacts

Public ContactYasuo Okumura

Nihon University School of Medicine Division of Cardiology, Department of Medicine

okumura.yasuo@nihon-u.ac.jp03-3972-8111

Outcome results